CAR-T cell therapy shows early promise against autoimmune disease
Clinical researchers are reporting early positive outcomes using CAR-T cell therapy — previously reserved for cancer — to achieve drug-free remission in treatment-resistant lupus, myositis, and systemic sclerosis, with some patients staying in remission for over a year.
- Engineered T cells target and deplete autoreactive B cell populations driving autoimmune damage
- Small cohort: 15 of 18 refractory lupus patients achieved remission at 12 months off standard immunosuppressants
- Significant toxicity risk and high manufacturing cost remain barriers to broad clinical use